Roche Holding AG
RHHBYOTCAlpha Score of 51 reflects moderate overall profile with moderate momentum, moderate value. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
| Politician | Date | Type | Amount |
|---|---|---|---|
| Bruce Westerman R-AR | 2025-04-21 | sale | $1k – $15k |
| Bruce Westerman R-AR | 2025-03-03 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ | 2024-07-23 | purchase | $1k – $15k |
| Daniel Goldman NY | 2023-07-10 | sale | $50k – $100k |
| Daniel Goldman NY | 2023-03-31 | purchase | $1k – $15k |
| Daniel Meuser R-PA | 2023-02-28 | sale | $1k – $15k |
| Daniel Goldman NY | 2023-01-13 | purchase | $15k – $50k |
| Dwight Evans D-PA | 2022-11-14 | purchase | $1k – $15k |
Roche Holding AG is a leading pharmaceutical and diagnostics company based in Basel, Switzerland. As a pioneer in personalized healthcare, Roche dedicates itself to improving patient outcomes through scientific innovation and collaboration. Its pharmaceutical division focuses on developing drugs for oncology, immunology, infectious diseases, ophthalmology, and neuroscience, playing an essential role in advancing treatment options in these critical areas. The diagnostics division complements this by providing comprehensive laboratory solutions and pioneering in-vitro testing products, facilitating early and accurate disease diagnosis. Roche's strategic emphasis on research and development has solidified its position as an industry leader, exerting significant influence across the global healthcare sector. Through sustained investments in innovative therapies and diagnostic tools, Roche continues to drive advancements that shape modern medicine, impacting millions worldwide.
Earnings calendar coming soon. Subscribe to get notified when RHHBY reports next.
Get earnings alerts →